Outsourcing-Pharma presents its latest round up of movements in the pharma outsourcing sector, including appointments at PharmaNet, PPD, BASi and WorldCare Clinical.
Recognition of glass vial quality issues is supporting interest in West’s analytical capabilities and Crystal Zenith (CZ) products, new sizes of which are being developed, said a company VP.
Global biopharmaceutical company, Bristol-Myers Squibb will buy ZymoGenetics for $885m to become owner of a hepatitis C drug the companies are jointly developing.
AMRI recorded a $6.0m (€4.6m) operating loss in the second quarter as restructuring charges and the lack of milestone payments offset contract service gains.
Outsourcing-Pharma presents its latest round up of movements in the pharma outsourcing sector, including appointments at Harlan, OmniComm, Cedra, OmniComm and Clearstone.
in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including appointments at Xcellerex, Bristol-Myers Squibb and KV Pharmaceutical.
In-Pharmatechnologist presents its latest round up of movements in the pharma sector, including appointments at Merck & Co, MediGene and Medivation, as well as departures at Bristol-Myers Squibb and KV Pharmaceutical.
The recent wave of M&A will lead to manufacturing over-capacity at pharma companies but only a small number of these sites will be sold to CMOs, in part because of the facilities’ suboptimal locations, according to a report.
Cost cutting has sustained pharma profits in the faltering global economy, however top executives are starting to realise that reducing R&D capacity may not have been the smartest move in an era of weak pipelines and impending patent expiry, according...
Eli Lilly has agreed to acquire ImClone for $6.5bn and in doing so appears to have snatched the biotech away from Bristol-Myers Squibb (BMS), which first tabled a bid back in July.
R&D integration specialist Symyx Technologies says its Powdernium Workstation is integral to the new automated dry powder dispensing system developed by a "major" but as yet unidentified pharmaceutical company.
Bristol-Myers Squibb (BMS) has finally detailed its plans to trim
the fat and save cash, months after first revealing that big
changes would be on the cards.
The latest ethical reputations of the world's largest
pharmaceutical companies have been revealed, with GlaxoSmithKline
(GSK) emerging as big pharma's Mother Theresa, according to a
recently-released compilation by Geneva-based...
Construction has finally begun on Bristol-Myers Squibb's (BMS) new
biologics manufacturing facility in Massachusetts, with the company
upping its original investment estimates for construction from
$660m (€485.7m) to $750m.
Bristol-Myers Squibb (BMS) has announced its second collaboration
this year with a fellow big pharma firm, aimed once again at
reducing the inherent risk of drug development.
Bristol-Myers Squibb (BMS) has spent $3.65m (€2.78m) on an 89-acre
plot of land to build a new bulk biologics manufacturing facility
in Devens, Massachusetts.
In a deal worth up to $1.35bn (€1bn) AstraZeneca (AZ) have agreed
to co-develop and commercialise two of Bristol-Myers Squibb's (BMS)
late stage diabetes compounds.
US drug maker Bristol-Myers Squibb has said it will invest $200m
(€166m) to expand its Puerto Rico facility, driven by a thirst for
biologics that the firm is trying to quench, both in-house and
through contract manufacturing.
A $30.1m drop in licence and research revenue and the expensive
removal by rebel shareholders of its former CEO Gerard Soula last
June have taken drug delivery company Flamel from a net profit of
$12.5m (€10.3m) in 2004 to a net loss...
Bristol-Myers Squibb (BMS) has cut $400 million in annual expenses
over the last two years in order to boost its R&D pipeline and
achieve sales and earnings growth beginning in 2007.
Innovata has entered into a second agreement in which the
development of a combination asthma therapy could generate in
excess of £25 million (€37 million) in milestones and development
funding.
US drug major Bristol-Myers Squibb has turned to Celltrion, a
company based in South Korea, for the manufacture of biologic
drugs, in another example of companies 'offshoring' production to
Asia, reports Phil Taylor.
Rumours abound that Sankyo, Japan's second largest pharmaceutical
company, is in late-stage discussions with sixth-ranked Daiichi
Pharmaceuticals over a merger.
Germany drugmaker Schering is planning to reduce its headcount by
1,250 with most of the cuts coming in production. The company is
blaming increased cost pressures due to European and international
competition.
Rhodia Pharma Solutions' Chambers Works facility in New Jersey is
now up and running. The company supplies preclinical and clinical
trial materials and launch volumes of active pharmaceutical
ingredients (APIs) and intermediates...
US pharmaceutical giant Bristol-Myers Squibb (BMS) is to pay $150
million (€122 million) to settle an investigation in which
regulators claimed the company gave investors an inaccurate
representation of its financial performance by...
The number of novel pharmaceutical compounds approved for marketing
- a traditional benchmark for the industry's R&D performance -
has seen a welcome increase after years of declines.
DFB Pharmaceuticals has appointed Magnus Precht as the new
president at Phyton, a company specialising in plant cell
fermentation for the production of pharmaceutical which it acquired
last year.
DFB Pharmaceuticals has acquired fellow US company Phyton to gain
access to the latter's plant cell fermentation technology for the
manufacture of pharmaceuticals.
French pharmaceutical company Sanofi-Synthelabo has opened a new
manufacturing facility in Aquitaine for the production of two of
its top drugs, the antithrombotic Plavix (clopidogrel) and Aprovel
(irbesartan) for hypertension.
Ireland's Elan has said that its US-based drug delivery business,
NanoSystems, will not be part of the sell-off in assets forced by
its onerous debt burden. The company is also retaining its US acute
care products business.
Merck KGaA drops plans to build a €300m biomanufacturing plant in
Jena, Germany, on the grounds that late-stage product failures have
left plenty of free capacity in the contract sector. The company's
move suggests that the often-repeated...
